# Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors
Canonical URL: https://biopharmsignal.com/news/KURA/kura-oncology-reports-strong-clinical-activity-and-safety-with-darlifarnib-adagrasib-in-kras-g12c-mutated-solid-tumors
Ticker: KURA
Company: Kura Oncology
Source: Kura Oncology
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.kuraoncology.com
## Summary

– Tumor shrinkage observed in 77% of response-evaluable patients, including in heavily pretreated and KRASi-experienced patients – – ORRs were 67% in PDAC, 50% in NSCLC, and 29% in KRASi-naïve CRC patients – – Results reinforce darlifarnib’s potential as a precision combination agent across

## Article Body
– Tumor shrinkage observed in 77% of response-evaluable patients, including in heavily pretreated and KRASi-experienced patients – – ORRs were 67% in PDAC, 50% in NSCLC, and 29% in KRASi-naïve CRC patients – – Results reinforce darlifarnib’s potential as a precision combination agent across
## Recent Company News
- 2026-07-03 11:30 EST — [Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/KURA/kura-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-32057cde) — Source: Kura Oncology
- 2026-06-25 13:46 EST — [Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML](https://biopharmsignal.com/news/KURA/kura-oncology-and-kyowa-kirin-report-encouraging-long-term-results-for-ziftomenib-7-3-combination-in-newly-diagnosed-aml) — Source: Kura Oncology
- 2026-06-25 13:46 EST — [Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy](https://biopharmsignal.com/news/KURA/kura-oncology-highlights-darlifarnib-s-potential-as-a-foundational-combination-platform-for-kras-mutant-cancers-and-outlines-development-strategy) — Source: Kura Oncology
- 2026-06-25 13:46 EST — [Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML](https://biopharmsignal.com/news/KURA/kura-oncology-and-kyowa-kirin-announce-publication-in-blood-of-ziftomenib-plus-venetoclax-azacitidine-combination-in-patients-with-r-r-npm1-m-aml) — Source: Kura Oncology
- 2026-06-25 13:46 EST — [Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors](https://biopharmsignal.com/news/KURA/kura-oncology-reports-strong-clinical-activity-and-safety-with-darlifarnib-adagrasib-in-kras-g12c-mutated-solid-tumors) — Source: Kura Oncology
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)